Epigral informs about unaudited financial results

02 Aug 2025 Evaluate
Pursuant to Regulations 30, 33 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Epigral has informed that the Board of Directors of Epigral (Formerly known as Meghmani Finechem) [‘the Company’] at its meeting held today i.e. Saturday, 2nd August, 2025 has discussed, approved, and taken on record the following matter: 1. Approved Un-Audited (Standalone & Consolidated) Financial Results of the Company for the First Quarter ended on 30th June, 2025; and took on record ‘Limited Review Report’ thereon issued by SRBC & Co LLP, Statutory Auditors of the Company; 2. Approved the proposal of raising funds up to a sum of Rs 400 Crores by way of issuance of non-convertible debentures, bonds and/or other debt securities etc. through permissible mode(s) within the borrowing limits of the Company, in one or more tranches / series, over a period of time and subject to such regulatory and other approvals as may be required. A copy of the approved Un-Audited Financial Results along with Limited Review Report are enclosed. The meeting commenced at 11:30 am and concluded at 12:50 pm at the Registered Office of the Company situated at Ahmedabad.

The above information is a part of company’s filings submitted to BSE.

Epigral Share Price

1468.90 -7.60 (-0.51%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
BASF India 4039.90
Tata Chemicals 773.85
SRF 2886.20
Pidilite Inds. 1474.70
Deepak Nitrite 1565.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×